Introduction The treatment landscape of hepatocellular carcinoma (HCC) has significantly
changed over the last 5 years with multiple options in the frontline, second line, and beyond …

Objective Lenvatinib and sorafenib are first-line oral multikinase inhibitors approved for the
treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the primary …

Background and aims Atezolizumab plus bevacizumab and lenvatinib have not been
compared in a randomised controlled trial. We conducted a retrospective multi-centre study …

Introduction The aim of this retrospective proof-of-concept study was to compare different
second-line treatments for patients with hepatocellular carcinoma and progressive disease …

Conclusions: This study indicates that DOCK2 controls CD8+ T-cell infiltration in HCC, and
cholesterol sulfate synthesized by sulfotransferase 2B1 in tumor cells promotes effector T …

Background A growing body of evidence suggests that non-viral hepatocellular carcinoma
(HCC) might benefit less from immunotherapy. Materials and methods We carried out a …

Purpose The purpose of this study is to compare response rates of lenvatinib and
atezolizumab plus bevacizumab, in first-line real-world setting. Methods Overall cohort …

Introduction The best first-line treatment for patients with advanced hepatocellular carcinoma
(HCC) and Child–Pugh (CP) class B remains unknown. The aim of the present study was to …

Background Atezolizumab plus bevacizumab has recently been approved as a new first-line
standard of care for patients with unresectable hepatocellular carcinoma (HCC). Objective …

Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer-
related death. The remarkable improvements in treating HCC achieved in the last years …